02:23 AM EDT, 09/15/2026 (MT Newswires) -- GSK (GSK.L) said Tuesday it agreed to purchase a potential best-in-class trispecific T cell-engager from Chinese biotech Chimagen Biosciences for up to $750 million. Under the terms of the agreement, the British drugmaker will secure full global rights to the TCE program for an upfront fee, with Chimagen also eligible to receive success-based development and commercial milestone payments. GSK plans to begin early-stage trials to evaluate the asset as a potential treatment for multiple myeloma in 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.